CBU
SLS icon

CIBC Bancorp USA’s SELLAS Life Sciences SLS Stock Holding History

CIBC Bancorp USA’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$17.3K Buy
+10,736
New +$19.1K ﹤0.01% 1459

Other funds holding SLS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CIBC Bancorp USA's SLS Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in SELLAS Life Sciences (SLS) in Q3 2025: 10,736 shares worth $17.3K. The stake represents ﹤0.01% of the portfolio and ranks #1459 among its holdings.

94 funds tracked by Wall St. Rank hold SLS as of Q3 2025.

  • CIBC Bancorp USA held 10,736 shares of SELLAS Life Sciences worth $17.3K as of Q3 2025.
  • SELLAS Life Sciences was a new CIBC Bancorp USA position in Q3 2025.
  • SELLAS Life Sciences made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1459 holding.
  • 94 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.